Article thumbnail
Location of Repository

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

By Eduardo Pimenta and Suzanne Oparil


The renin–angiotensin–aldosterone system (RAAS) is a key mediator of blood pressure (BP) and volume regulation in both normotensive and hypertensive persons. Stimulation of RAAS also contributes to hypertension-related target organ damage. The renin–angiotensinogen reaction is the first and rate-limiting step in the generation of angiotensin II (Ang II) and has been a target of antihypertensive drug development for decades. Aliskiren is the first in a new class of orally effective direct renin inhibitors (DRIs) and is approved for the treatment of hypertension in humans. It effectively reduces BP in the general population of hypertensive patients and has a tolerability and safety profile similar to placebo. Aliskiren has favorable effects on vascular inflammation and remodeling, on neurohumoral mediators of various forms of cardiovascular disease, including heart failure, and on proteinuria in diabetic patients. Additional outcome trials are needed to establish the role of this novel class of antihypertensive medication in preventing cardiovascular disease morbidity and mortality

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises.
  2. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design.
  3. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.
  4. Angiotensin II supression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril.
  5. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropaty.
  6. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies.
  7. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
  8. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans.
  9. Direct renin inhibition with aliskiren in obese patients with arterial hypertension.
  10. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both, on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
  11. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
  12. (2008). Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail.
  13. (2007). Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized double-blind trial. Lancet.
  14. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
  15. (2009). Efficacy of Aliskiren in PostMyocardial Infarction Patients (ASPIRE).
  16. (2008). Efficacy of aliskiren/ hydrochlorothiazide single-pill combinations in aliskiren nonresponders. Blood Press Suppl.
  17. Energy metabolism in human renin-gene transgenic rats: does renin contribute to obesity?
  18. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.
  19. (1994). Proteolytic processing of human prorenin in renal and non-renal tissues. Kidney Int.
  20. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
  21. Renin inhibition in hypertension.
  22. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
  23. (2008). Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients? Curr Opin Nephrol Hypertens.
  24. (2008). Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering? Cardiol Clin.
  25. (2005). Renin inhibitors.
  26. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren.
  27. The renin-angiotensin system and vascular hypertrophy.
  28. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.